Business Description
Forte Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US34962G2084
Share Class Description:
FBRX: Ordinary SharesTotal Employee Number:
22Description
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.63 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.9 | |||||
3-Year EPS without NRI Growth Rate | 38.2 | |||||
3-Year FCF Growth Rate | 33.5 | |||||
3-Year Book Growth Rate | -53.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 93.57 | |||||
9-Day RSI | 90.67 | |||||
14-Day RSI | 86.04 | |||||
3-1 Month Momentum % | -52.07 | |||||
6-1 Month Momentum % | -29.56 | |||||
12-1 Month Momentum % | 46.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.75 | |||||
Quick Ratio | 2.75 | |||||
Cash Ratio | 2.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -148.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -116.98 | |||||
ROA % | -94.27 | |||||
ROIC % | -2939.66 | |||||
3-Year ROIIC % | -1852.51 | |||||
ROC (Joel Greenblatt) % | -61874.6 | |||||
ROCE % | -117.79 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 14.5 | |||||
Price-to-Tangible-Book | 14.5 | |||||
EV-to-EBIT | -10.93 | |||||
EV-to-EBITDA | -10.94 | |||||
EV-to-FCF | -14.16 | |||||
| Price-to-Net-Current-Asset-Value | 15.3 | |||||
| Price-to-Net-Cash | 18.45 | |||||
Earnings Yield (Greenblatt) % | -9.15 | |||||
FCF Yield % | -6.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FBRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Forte Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.64 | ||
| Beta | 5.0244 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 1.77 | ||
| Volatility % | 86.62 | ||
| 14-Day RSI | 86.04 | ||
| 14-Day ATR ($) | 3.289377 | ||
| 20-Day SMA ($) | 21.449 | ||
| 12-1 Month Momentum % | 46.84 | ||
| 52-Week Range ($) | 9.1 - 45.36 | ||
| Shares Outstanding (Mil) | 20.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Forte Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Forte Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 34 days | ||
| General meeting for 2026 | 2026-05-29 09:00 | 20.77 (-2.99%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 24.02 (-7.44%) | ||
| Annual report for 2025 | 2026-03-31 | 26.32 (+2.77%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 26.32 (+2.77%) | ||
| TD Cowen 46 th Annual Healthcare Conference | 2026-03-04 13:50 | 30.42 (+0.13%) | ||
| Guggenheim Emerging Outlook: Biotech Summit | 2026-02-11 08:30 | 29.48 (-0.84%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 13.84 (-3.42%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 10.57 (-0.75%) |
Show
Entries
Forte Biosciences Inc Frequently Asked Questions
What is Forte Biosciences Inc(FBRX)'s stock price today?
The current price of FBRX is $43.92. The 52 week high of FBRX is $45.36 and 52 week low is $9.10.
When is next earnings date of Forte Biosciences Inc(FBRX)?
The next earnings date of Forte Biosciences Inc(FBRX) is 2026-08-14 Est..
Does Forte Biosciences Inc(FBRX) pay dividends? If so, how much?
Forte Biosciences Inc(FBRX) does not pay dividend.
Guru Commentaries on NAS:FBRX
No articles.
Press Release
Articles on Forte Biosciences Inc
Forte Biosciences (FBRX) Reports Encouraging Phase 1b Study Outcomes for Vitiligo Treatment
1 day ago
Headlines
See More- 1
Jul 09, 2026
Forte Bio surges on early-stage trial data for vitiligo therapy
Seeking Alpha • 10:16am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers